UNH
UNITEDHEALTH GROUP INCNYSEValuation snapshot
Below base casePrice is between the bear and base cases.
Price captured with valuation · Valuation Sep 5, 2026
What drives UNH's base case?
base-case thesisAfter a brutal 2025 in which medical costs spiked and profitability briefly cratered, UnitedHealth has spent 2026 deliberately trading membership for pricing discipline in its Medicare Advantage business, and management has already raised its full-year guidance twice on the back of that discipline. The base case takes management's own playbook at face value: revenue growth reaccelerates gradually as repricing finishes and Optum's pharmacy and health-services businesses keep growing, while operating margins recover toward, but not fully back to, their pre-2025 highs. Taxes and reinvestment normalize toward their multi-year historical averages rather than either 2025's anomalies or an optimistic best case.
What shapes the assumptions
Management's own raised FY2026 guidance and improving MA retention
adjusted EPS guidance raised to $19.50-$20 from $18.25+
Raises revenue growth
Stated Medicare Advantage margin recovery targets
MA margin trending to upper half of 2-4% band by 2027
Raises operating margin
2025 tax rate normalizes back to historical average
effective tax rate reverting from 12.9% (2025) toward 23.8% (2024) norm
Informs tax rate
Balanced capex, bolt-on M&A and larger buyback program
capex ~0.8% of revenue plus $5B+ 2026 buyback
Informs reinvestment
Decade-long track record of above-GDP revenue compounding
revenue growth from $94.2B (2010) to $447.6B (2025)
Raises terminal growth
Each driver links a business metric to the forecast assumption it shapes — the basis for this case, not investment advice.
Why the gap?
The market is pricing this as if revenue grows 3.9% a year. Over the last 5 years it grew 10.6% a year — so the price assumes less than it has delivered.
What else could explain it?›
- Or, holding growth steady
- the price is also consistent with a 7.0% operating margin, against the 7.5% assumed here.
- How confident is this estimate?
- Robustness 55.0/10 (Moderate) — some of any gap is our own uncertainty rather than disagreement.
- What would change the answer?
- Which assumption this valuation swings on, and by how much.
Many combinations of assumptions reproduce the same price. These are ways to read what the market might be expecting, not the market's actual view. How this is worked out
Research & assumptions
Inspect the valuation thesis, cases, risks, evidence, and model inputs.
View details
Research & assumptions
Inspect the valuation thesis, cases, risks, evidence, and model inputs.
Three independently researched cases generated automatically from published financials. Every assumption is justified and cited; the discount rate is computed from researched market inputs.
Company value drivers
Ranked operating metrics and the valuation assumptions they influence.
1. Consolidated medical care ratio (quarterly)
The share of premium revenue paid out in medical claims; the single biggest driver of UnitedHealthcare's margin recovery or deterioration.
86.7%
reported2. UnitedHealthcare Medicare Advantage membership (period-end)
Number of enrolled Medicare Advantage members; the main lever behind the deliberate trade-off between near-term growth and margin recovery.
7,565,000
reported3. Consolidated revenue growth, year-over-year (quarterly)
The quarterly pace of top-line growth, the most direct real-time read on whether the revenue forecast path is tracking.
0.4%
reported4. Capital expenditures as % of revenue (annual)
Capex relative to revenue, a proxy for how much of the business's growth requires reinvestment versus being available as free cash flow.
0.8%
derived5. Effective income tax rate (annual)
The provision for income taxes as a share of pre-tax earnings, directly setting the DCF tax-rate assumption and flagging one-off distortions.
12.9%
reportedBase inputs from financials
source period →Base revenue (TTM)
$450.1B
Diluted shares
906,000,000
Net cash
-$40.9B
Bear
low confidence$193.98
IV / share
-51.2% vs $397.14
- Explicit cash flows
- $49.58
- Terminal value
- $189.56
- Net cash
- -$45.16
- Intrinsic value / share
- $193.98
97.7% of the value rests on the terminal value — high dependency. A small change to terminal growth moves the valuation a lot — see terminal growth below.
Revenue growth2.0% → 3.0% → 3.5% → 4.0% → 4.0%medium
How derived: H1 2026 revenue grew only ~1.2% YoY (Q1 +1.96%, Q2 +0.37%) as UnitedHealthcare deliberately shed roughly 0.9M Medicare Advantage members (8.445M at YE2025 to 7.565M at Q2 2026) to reprice its book; bear case assumes DOJ scrutiny and elevated cost trend keep growth muted before only a slow reacceleration toward mid-single digits.
Why this confidence: Two consecutive quarters of actual reported deceleration (Q1 +2.0%, Q2 +0.4%) anchor the near-term path ↑, Five-year horizon requires assuming the DOJ investigation outcome and PBM reform trajectory, both unresolved ↓, Management already reversed course once in 2026 by raising guidance, showing the trend can turn faster than a bear path assumes ↓
Measured by
- Consolidated medical care ratio (quarterly)86.7%reported
- UnitedHealthcare Medicare Advantage membership (period-end)7,565,000reported
- Consolidated revenue growth, year-over-year (quarterly)0.4%reported
Evidence for
- Q2 2026 revenue grew only 0.37% YoY, the slowest quarterly pace in over a decade, coinciding with active MA membership shedding.[UNH Reports Second Quarter 2026 Results]· primary
- UnitedHealthcare initially projected losing 1.3-1.4 million Medicare Advantage members in 2026 as it prioritizes margin recovery over enrollment growth.[UnitedHealthcare's 'deliberate trade-off' for margin recovery]· secondary
Evidence against
- UnitedHealth raised full-year 2026 adjusted EPS guidance to $19.50-$20 (from $18.25+) after a Q2 beat, and revised its projected MA membership decline down to ~1.1 million from 1.3-1.4 million on better-than-expected retention.[UnitedHealth raises 2026 guidance again as cost controls pay off in Q2]· secondary
Operating margin5.5%medium
How derived: Consolidated operating margin cratered from 8.05%-8.32% in early 2025 to just 0.34% in Q4 2025 before recovering to 7.13%-8.05% in H1 2026; bear case assumes the recovery stalls in the mid-single digits as elevated medical cost trend and DOJ-related compliance costs persist, well below the ~8% margins UNH posted before the 2025 blowup.
Why this confidence: Company's own guidance points to steady margin improvement, working against a stalled-recovery thesis ↓, Five quarters of directly reported margins (0.3% to 8.3%) give a real observed range to anchor a conservative estimate within ↑, DOJ investigation outcome (fines, mandated business changes) is unknown and could be more severe than assumed ↓
Measured by
- Consolidated medical care ratio (quarterly)86.7%reported
- UnitedHealthcare Medicare Advantage membership (period-end)7,565,000reported
Evidence for
- UNH's CFO said Q2 2026 results are 'not a reflection of trend bending or coming under control, but rather our efforts to start pushing down what is already an elevated number.'[Full Transcript: UnitedHealth Group Q2 2026 Earnings Call]· primary
Evidence against
- Medicare Advantage margins are expected to finish 2026 above 3%, roughly 50bps better than 2025, on tighter benefit design and pricing actions.[UnitedHealthcare's 'deliberate trade-off' for margin recovery]· secondary
Tax rate26.0%low
How derived: Effective tax rate was 20.5% (2023), 23.8% (2024) and an anomalous 12.9% (2025, attributed by the company to divestiture losses and depressed pretax income); bear case assumes normalization above the historical range plus incremental cost from a possible DOJ-related settlement or lost deductions.
Why this confidence: Three years of reported effective tax rates give a directly observed historical band (20.5%-23.8% ex-2025 anomaly) ↑, Assumes a specific incremental settlement/penalty effect that is speculative and not yet confirmed by any filing ↓
Measured by
- Effective income tax rate (annual)12.9%reported
Evidence for
- 2025's unusually low 12.9% effective tax rate was explicitly attributed to one-off divestiture losses and lower pretax income, meaning some reversion upward is likely.[UNH 2025 Form 10-K]· primary
Evidence against
- No disclosed tax-specific penalty is currently associated with the DOJ investigation, and UNH's historical effective rate has topped out near 24%, not 26%.[UNH 2024 Form 10-K]· primary
Reinvestment rate45.0%low
How derived: FY2025 capex was about $3.6B (~0.8% of revenue), but the bear case assumes higher effective reinvestment as UNH spends on compliance systems, legal defense and IT remediation tied to the DOJ probe without a commensurate growth payoff, while deleveraging toward Moody's cited ~2.0x debt/EBITDA target competes for cash.
Why this confidence: Directly opposed to the most recent capital-allocation signal (bigger buyback), a real tension in this assumption ↓, Capex-to-revenue ratio itself is low and stable historically (~0.8-0.9%), so the compliance-spend adjustment is judgment, not observed data ↓
Measured by
Evidence for
- Moody's negative outlook cites the need for debt/EBITDA to improve to 2.0x or better and clearer interest coverage, implying capital could be diverted from growth investment toward balance-sheet repair.[Moody's changes UnitedHealth's outlook to negative, affirms A2 rating]· secondary
Evidence against
- UNH actually raised 2026 buyback guidance to at least $5 billion from an initial $2.5 billion, signaling more capital returned to shareholders rather than reinvested defensively.[Full Transcript: UnitedHealth Group Q2 2026 Earnings Call]· primary
Terminal growth2.0%low
How derived: Set below the base case to reflect a scenario where continued Medicare Advantage regulatory tightening and DOJ-driven business-model changes structurally cap UNH's ability to outgrow the broader US economy in perpetuity.
Why this confidence: Terminal growth is a single number 5+ years out with no direct observation possible ↓, Anchored to a conservative macro band (near/below long-run nominal GDP) rather than aggressive company-specific extrapolation ↑
No tracked driver measures this assumption yet.
Evidence for
- DOJ scrutiny of Medicare Advantage risk-adjustment coding is an industry-wide, multi-year theme, supporting a structurally lower long-run growth ceiling for UNH's largest segment.[UnitedHealth facing DOJ investigation over Medicare billing]· secondary
Evidence against
- UNH's revenue still grew from $400.3B (2024) to $447.6B (2025), +11.8%, even amid the DOJ probe and cost-trend shock, arguing the long-run ceiling may be higher than this case assumes.[UNH 2025 Form 10-K]· primary
Base
medium confidence$428.93
IV / share
+8.0% vs $397.14
- Explicit cash flows
- $86.89
- Terminal value
- $387.20
- Net cash
- -$45.16
- Intrinsic value / share
- $428.93
90.3% of the value rests on the terminal value — high dependency. A small change to terminal growth moves the valuation a lot — see terminal growth below.
Revenue growth3.5% → 5.0% → 6.0% → 6.5% → 6.5%medium
How derived: Builds off management's raised FY2026 guidance (adjusted EPS $19.50-$20, up from $18.25+) after the Q2 2026 beat, with growth reaccelerating from H1 2026's ~1.2% pace as Medicare Advantage repricing completes, membership stabilizes, and Optum Rx/Optum Health continue their 2025 growth (+16%/-3% respectively), landing below the 2015-2025 historical average (~10-12%) given UNH's much larger revenue base.
Why this confidence: Directly grounded in the company's own raised guidance, a primary disclosure ↑, Requires assuming a reacceleration that has not yet shown up in reported quarterly growth numbers ↓
Measured by
- Consolidated medical care ratio (quarterly)86.7%reported
- UnitedHealthcare Medicare Advantage membership (period-end)7,565,000reported
- Consolidated revenue growth, year-over-year (quarterly)0.4%reported
Price implies: 3.9% vs our 5.5% — one of several sets that fit this price
Evidence for
- UNH raised full-year 2026 outlook after a Q2 beat, and MA member retention already came in better than feared (decline revised to ~1.1M from 1.3-1.4M).[UnitedHealth raises 2026 guidance again as cost controls pay off in Q2]· secondary
Evidence against
- Q2 2026 revenue growth of just 0.37% YoY was the slowest in over a decade, and the CFO said cost trend is not yet 'bending.'[Full Transcript: UnitedHealth Group Q2 2026 Earnings Call]· primary
Operating margin7.5%medium
How derived: Operating margin recovered from a Q4 2025 trough of 0.34% to 7.13%-8.05% in H1 2026; base case assumes continued gradual recovery toward, but not fully back to, the ~8-9% margins UNH posted in 2021-2024, consistent with management's stated target of reaching the upper half of its 2-4% Medicare Advantage margin band by 2027.
Why this confidence: Management has given explicit, quantified multi-year margin targets (2-4% MA band, upper half by 2027) ↑, 2025 showed margins can deteriorate very quickly (8.3% to 0.3% in three quarters), so the recovery path is not guaranteed ↓
Measured by
- Consolidated medical care ratio (quarterly)86.7%reported
- UnitedHealthcare Medicare Advantage membership (period-end)7,565,000reported
Price implies: 7.0% vs our 7.5% — one of several sets that fit this price
Evidence for
- Medicare margins are expected to finish 2026 above 3% and reach the upper half of the 2-4% target range in 2027.[UnitedHealthcare's 'deliberate trade-off' for margin recovery]· secondary
Evidence against
- The CFO cautioned Q2 2026 results reflect 'pushing down an elevated number' rather than the cost trend actually bending, implying recovery could stall short of the target.[Full Transcript: UnitedHealth Group Q2 2026 Earnings Call]· primary
Tax rate24.0%high
How derived: Reverts to the pre-2025 historical effective tax rate norm (20.5% in 2023, 23.8% in 2024) after the anomalous 12.9% in 2025 that the 10-K attributes to divestiture losses and depressed pretax income.
Why this confidence: Three years of directly reported effective tax rates bound this estimate tightly ↑, Company explains the 2025 anomaly, reducing ambiguity about which rate is the 'true' normalized one ↑
Measured by
- Effective income tax rate (annual)12.9%reported
Evidence for
- The 10-K explicitly attributes the 2025 tax-rate drop to one-off divestiture and pretax-income effects, implying reversion toward the historical range.[UNH 2025 Form 10-K]· primary
Evidence against
- If pretax income remains depressed relative to 2024, similar mechanical tax-rate volatility could recur and the rate could undershoot 24% again.[UNH 2025 Form 10-K]· primary
Reinvestment rate35.0%medium
How derived: FY2025 capex of ~$3.6B (0.8% of revenue) plus continued bolt-on M&A (Optum's history of deals like Change Healthcare and LHC Group) and a step-up to at least $5B of 2026 buybacks signal a balanced capital allocation between growth investment and shareholder returns.
Why this confidence: Capex-to-revenue ratio has been stable and low for several years (~0.8-0.9%), a directly observed base rate ↑, Blends capex with judgmental M&A/reinvestment assumptions not separately itemized in filings ↓
Measured by
Evidence for
- UNH raised 2026 buyback guidance to at least $5 billion (from $2.5 billion) while maintaining capex and AI investment plans, evidencing balanced capital allocation.[Full Transcript: UnitedHealth Group Q2 2026 Earnings Call]· primary
Evidence against
- A ~40% debt-to-capital target and Moody's negative outlook could push more cash toward deleveraging rather than growth reinvestment.[Moody's changes UnitedHealth's outlook to negative, affirms A2 rating]· secondary
Terminal growth2.5%medium
How derived: Set near long-run US nominal GDP growth (real GDP ~2% plus inflation ~2%, moderated for a mature, heavily regulated payer/PBM franchise), consistent with typical terminal assumptions for a large-cap company of UNH's scale.
Why this confidence: Anchored to widely used macro proxies (long-run nominal GDP) rather than firm-specific extrapolation, a standard and defensible convention ↑, No single data point can validate a terminal assumption; it is inherently a judgment call over an infinite horizon ↓
No tracked driver measures this assumption yet.
Evidence for
- UNH's revenue compounded well above GDP for over a decade (from $94.2B in 2010 to $447.6B in 2025), supporting durable above-GDP secular demand even at terminal maturity.[UNH 2025 Form 10-K]· primary
Evidence against
- Regulatory and reimbursement pressure (DOJ probe, PBM reform scrutiny) could structurally cap long-run growth below the assumed rate.[DOJ's criminal probe into UnitedHealth extends to Optum Rx, physician reimbursement]· secondary
Bull
low confidence$688.13
IV / share
+73.3% vs $397.14
- Explicit cash flows
- $118.01
- Terminal value
- $615.28
- Net cash
- -$45.16
- Intrinsic value / share
- $688.13
89.4% of the value rests on the terminal value — high dependency. A small change to terminal growth moves the valuation a lot — see terminal growth below.
Revenue growth4.5% → 6.5% → 8.0% → 8.5% → 8.5%low
How derived: Assumes the margin-recovery playbook works faster than guided: MA repricing completes by 2027, allowing UNH to resume competing for membership, the DOJ investigation resolves without material sanction, and Optum Rx/Health (which grew 16% and roughly -3% respectively in 2025 but with Rx accelerating) reaccelerate, pushing blended growth back toward the 8-13% range UNH posted in 2021-2023, tempered for its now much larger revenue base.
Why this confidence: Requires several favorable, currently unconfirmed events (fast DOJ resolution, membership regrowth) to compound together ↓, Grounded in the same guidance-raise trend that has held for two consecutive quarters in 2026 ↑
Measured by
- Consolidated medical care ratio (quarterly)86.7%reported
- UnitedHealthcare Medicare Advantage membership (period-end)7,565,000reported
- Consolidated revenue growth, year-over-year (quarterly)0.4%reported
Evidence for
- UNH raised 2026 EPS guidance twice within the year, and member retention beat internal expectations (decline revised down to ~1.1M from 1.3-1.4M).[UnitedHealth raises 2026 guidance again as cost controls pay off in Q2]· secondary
Evidence against
- Q1 and Q2 2026 growth (1.96% and 0.37%) are far below this trajectory today, and the CFO said cost trend has not yet bent.[Full Transcript: UnitedHealth Group Q2 2026 Earnings Call]· primary
Operating margin9.0%low
How derived: Assumes UNH's disclosed $1.5B AI investment in care delivery, administrative and pharmacy productivity, combined with Medicare Advantage repricing reaching the top of its 2-4% margin band, pushes consolidated operating margin modestly above the ~8.8% peak UNH achieved around 2021, ahead of management's own 2027 timeline.
Why this confidence: Exceeds any margin UNH has actually reported historically, so there is no direct precedent ↓, Based on a specific, disclosed $1.5B AI investment program rather than a vague productivity story ↑
Measured by
- Consolidated medical care ratio (quarterly)86.7%reported
- UnitedHealthcare Medicare Advantage membership (period-end)7,565,000reported
Evidence for
- UNH is deploying $1.5 billion into AI to streamline operations while simultaneously shrinking membership and exiting unprofitable contracts, a direct margin lever.[UnitedHealth raises 2026 guidance again as cost controls pay off in Q2]· secondary
Evidence against
- UNH's historical peak consolidated operating margin (~8.8% around 2021) was achieved before the DOJ investigation and cost-trend shock existed, so exceeding it is a high bar.[UNH annual revenue and margin history]· primary
Tax rate23.5%low
How derived: Slightly below the pre-2025 historical norm (23.8% in 2024), reflecting a modestly favorable mix shift as Optum's technology and services lines scale, with no assumed DOJ-related tax penalty.
Why this confidence: Small, narrow deviation from the base case reduces the risk of the assumption being far off ↑, Relies on a mix-shift tax benefit that is not separately disclosed or quantified by the company ↓
Measured by
- Effective income tax rate (annual)12.9%reported
Evidence for
- UNH's reported effective tax rate was 20.5% in 2023, showing the rate has historically been able to run below 24%.[UNH 2023 Form 10-K]· primary
Evidence against
- 24% approximates the practical floor UNH has shown outside one-off anomalies like 2025's 12.9%, so sustained sub-24% rates are not the clear norm.[UNH 2024 Form 10-K]· primary
Reinvestment rate30.0%low
How derived: Assumes AI-driven productivity gains reduce the capital intensity needed to support each dollar of growth, so a lower share of NOPAT needs reinvestment even as the buyback program (raised to at least $5B for 2026) continues alongside disciplined, high-return bolt-on M&A.
Why this confidence: Assumes a productivity payoff from the AI program that has not yet shown up in reported reinvestment or margin data ↓, Consistent with the company's demonstrated willingness to raise capital returned to shareholders in 2026 ↑
Measured by
Evidence for
- UNH raised 2026 share repurchase guidance from $2.5B to at least $5B while reaffirming AI investment plans, showing it can fund growth and returns simultaneously.[Full Transcript: UnitedHealth Group Q2 2026 Earnings Call]· primary
Evidence against
- Capex has trended up in absolute dollars in recent years (toward $3.6B in 2025) even as revenue growth slowed, suggesting reinvestment needs may not fall as assumed.[UNH 2025 Form 10-K]· primary
Terminal growth3.0%low
How derived: Reflects continued above-GDP secular healthcare spending growth (aging population, chronic disease prevalence, Optum's expanding value-based and technology-enabled care model), allowing UNH to sustain modestly above-nominal-GDP growth in perpetuity.
Why this confidence: Terminal growth cannot be directly observed or tested against any single reported figure ↓, Extrapolates from a well-documented decade of historical outgrowth of GDP in reported revenue ↑
No tracked driver measures this assumption yet.
Evidence for
- UNH's revenue compounded at 12%-20% annually through the mid-2010s to 2023 (e.g. +20.4% in 2015, +17.7% in 2016, +14.6% in 2023) as it diversified into Optum, well above GDP, supporting a structurally higher long-run ceiling.[UNH 2025 Form 10-K]· primary
Evidence against
- A 3% perpetual growth rate implies UNH permanently outgrows long-run US nominal GDP, a strong assumption for a company already generating $450B of annual revenue.[Analyst reasoning from company scale]· estimate
Valuation robustness
reliability of the estimate, not a stock rating55 / 100 · Moderate
Formula v1.0.0. Higher means a more reliable estimate — not a recommendation.
Quality checks
Automated model-risk flags — warnings, not recommendations.
- 90% of the intrinsic value rests on the terminal value — a small change to terminal growth moves the valuation a lot.→ terminal growth
Per-share economics
Business growth after changes in the diluted share count.
| Period | Revenue growth | FCF/share | FCF/share growth | Shares | Share growth |
|---|---|---|---|---|---|
| Q3 2024 | 9.2% | 13.93 | 115.0% | 930M | -0.6% |
| Q1 2025 | 9.8% | 4.97 | 1041.6% | 918M | -0.4% |
| Q2 2025 | 12.9% | 6.93 | 9.1% | 910M | -1.9% |
| Q3 2025 | 12.2% | 5.57 | -60.0% | 908M | -2.4% |
| Q1 2026 | 2.0% | 8.95 | 80.4% | 910M | -0.9% |
| Q2 2026 | 0.4% | 11.32 | 63.4% | 906M | -0.4% |
Valuation history every run
History builds as the valuation is recalculated — this is the first recorded run.
Market inputs researched
The 10-year US Treasury note yield closed at 4.78% on September 4, 2026, the standard risk-free rate proxy for a USD-denominated DCF.
Yahoo Finance reports a 5-year monthly beta of 0.63 for UNH against the S&P 500, corroborated by stockanalysis.com's 0.62, reflecting UNH's historically defensive, lower-volatility profile as a diversified health-benefits/services company even after the 2025 stock decline.
Aswath Damodaran's 2026 edition / most recent (July 2026) update puts the implied US equity risk premium at 4.45%, derived from current S&P 500 prices and forward cash-flow expectations.
UNH last traded at $397.14 per Yahoo Finance/Investing.com quotes as of early September 2026.
UNH carries a Moody's A2 rating with a negative outlook; adding a representative A-to-BBB corporate credit spread to the 4.78% 10-year Treasury yield, and cross-checking against the ICE BofA BBB US Corporate Index effective yield of 5.59% (August 2026) and UNH's own disclosed revolving-credit-facility draw rates of 4.2%-6.8% (FY2025 10-K), implies a pretax cost of debt of roughly 5.5%.
Generated 9/5/2026, 4:56:40 PM · pipeline v1.2.0